Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Muvz is a proprietary botanical combination of *Vitex negundo* (five-leaf Chinese chaste tree) and *Zingiber officinale* (ginger) developed by Enovate Biolife and marketed by OmniActive Health Technologies. The formula is designed to support joint health and alleviate musculoskeletal discomfort, specifically targeting knee joint pain and low back pain. It utilizes a water extract of *Vitex negundo* leaves and twigs combined with a supercritical CO2 extract of *Zingiber officinale* rhizomes. Muvz exhibits analgesic, antioxidant, and anti-inflammatory properties, with clinical studies demonstrating same-day benefits for exercise-induced knee pain and significant improvements in mobility and flexibility. It is typically administered at a dosage of 200 mg twice daily and is positioned as a natural alternative for managing joint discomfort.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vitex negundo + zingiber officinale.